India Pharma Outlook Team | Tuesday, 19 May 2026
Indian pharma firms post strong FY26 revenue growth as major companies across the pharmaceutical and healthcare sectors reported solid sales expansion, strong Q4 recoveries, and improving operational performance.
Indian pharma firms post strong FY26 revenue growth despite margin pressure in some businesses, rising expansion costs, and continued pricing challenges in global markets.
Companies including Cupid Ltd, Alembic Pharmaceuticals, Alivus Life Sciences, Aarti Drugs, and KIMS Hospitals delivered mixed but largely positive performances during FY26, highlighting the resilience of India’s pharma and healthcare industry.
The earnings season showed strong demand across export markets, domestic formulations, specialty therapies, diagnostics, APIs, and hospital services. While some firms reported pressure on profitability because of expansion investments and higher costs, revenue momentum remained healthy across most segments. Export-led businesses and the US generics market continued to be major growth drivers for Indian pharma companies.
Cupid Ltd emerged as one of the biggest outperformers during FY26. The company reported a massive 93% jump in revenue along with a 165% surge in net profit, comfortably beating its own annual guidance. Strong export demand, rising B2B orders, growth in FMCG wellness products, and expansion in diagnostics supported the sharp rise in earnings. The company also benefited from strong operating leverage as EBITDA margins improved significantly during the year. Cupid has now projected aggressive growth targets for FY27 as it expands production capacity and strengthens its international presence.
Aditya Kumar Halwasiya, Chairman and Managing Director of Cupid Limited said: "We have delivered a historic performance in FY26, surpassing our annual guidance and reporting revenue of INR 358 Cr and net profit of INR 108 Cr. This performance reflects strong execution, improving operating leverage and sustained demand across our businesses, resulting in our strongest ever quarterly and full year performance.
Also Read: Role of Wellness in Corporate & Community Health
Alembic Pharmaceuticals also delivered a strong Q4 FY26 performance with net profit rising 29% year-on-year. The company’s US formulations business remained a major growth engine, supported by multiple product launches and fresh ANDA approvals. Alembic’s entry into the branded specialty pharmaceuticals segment in the US market marked an important strategic shift for the company. Domestic branded formulations and API businesses also reported stable growth, helping overall revenue expansion during the year.
Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments.
Alivus Life Sciences posted steady FY26 revenue growth but stood out because of its sharp margin expansion. EBITDA margins crossed management guidance and reached record levels during the year due to a better product mix, stronger CDMO recovery, and improved operating efficiency. The company also maintained a healthy balance sheet with strong cash generation and minimal debt, strengthening investor confidence in its long-term growth strategy.
Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, “The past two years under Nirma's ownership have been deeply fulfilling — a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth.
Aarti Drugs reported stable FY26 revenue growth along with a strong sequential recovery in Q4. Although margins remained under pressure because of higher input costs and pricing challenges in APIs, the company showed clear operational improvement compared to earlier quarters. Revenue growth remained steady while management continued investing in expansion and formulations growth opportunities.
Adhish Patil, CFO & COO, Aarti Drugs Limited said, "FY26 marked an important transition year for Aarti Drugs Limited, as the Company progressed through a major investment and commissioning cycle while navigating a challenging industry environment.
While revenue growth remained strong across the sector, profitability trends were mixed. KIMS Hospitals reported robust revenue growth during FY26 as patient volumes increased and new hospitals contributed to business expansion. However, net profits declined sharply because of rising employee expenses, depreciation costs, financing expenses, and operational costs linked to newly launched hospitals. Despite short-term pressure on margins, the company continued expanding bed capacity and strengthening its presence in key healthcare markets.
Across the pharma sector, companies continued facing challenges from global pricing pressure, higher raw material costs, regulatory expenses, and ongoing investments in manufacturing and research. However, improving demand in export markets, recovery in Pharma CDMO businesses, and strong domestic healthcare demand helped offset many of these pressures.
The broader Indian pharma industry also benefited from continued demand in the US generics market, increasing focus on specialty therapies, and rising investments in healthcare infrastructure. Many companies are now focusing on complex generics, branded specialty drugs, diagnostics, wellness products, and international expansion to improve long-term profitability and reduce dependence on traditional low-margin segments.
Industry analysts believe the sector remains well-positioned for future growth because of India’s manufacturing strength, growing export opportunities, and rising healthcare demand both domestically and globally. Capacity expansion projects, product pipeline development, and specialty market entries are expected to remain major growth themes during FY27.
Cupid Ltd is an Indian pharmaceutical and wellness company known for manufacturing condoms, personal lubricants, diagnostics products, and FMCG wellness products. The company has a strong export presence across global healthcare markets.
Alembic Pharmaceuticals is a leading Indian drugmaker with operations in branded formulations, APIs, and US generics. The company focuses on specialty pharmaceuticals, complex generics, and international market expansion.
Alivus Life Sciences operates in APIs, formulations, and CDMO services. The company is known for its strong operational efficiency, export business, and expanding global pharmaceutical footprint.
Aarti Drugs manufactures APIs, formulations, and specialty chemicals. The company serves both domestic and international pharmaceutical markets with a diversified product portfolio.
KIMS Hospitals is one of India’s major healthcare providers with multi-specialty hospitals across South India. The company focuses on affordable healthcare, hospital expansion, and advanced medical services.
.jpg)
.jpg)
